Baraliakos X, et al. Long-Term Evaluation of Secukinumab in Ankylosing Spondylitis: 5 Year Efficacy and Safety Results from a Phase 3 Trial. ACR 2018, abstract L13.
2,5 miljoen euro voor vaccin tegen auto-immuunziekten
apr 2020 | RA, Vaccinatie
nov 2022 | Psoriasis
nov 2020
okt 2020
aug 2020 | RA, SLE